Galux Unveils Breakthrough in AI-Driven Antibody Design with Broad Therapeutic Implications Galux, a South Korean biotech firm, showcases its new AI platform for antibody design, achieving unprecedented precision with vast therapeutic potential across eight disease targets.

Galux Unveils Breakthrough in AI-Driven Antibody Design with Broad Therapeutic Implications #South_Korea #Seoul #Biotech_Innovation #GaluxDesign #AI_Antibodies